FDA approves fewer new drugs in 2026 than 2027

Market overview

The FDA will approve 10% fewer new drugs in 2026 compared to 2025 due to regulatory instability and staffing challenges. Industry uncertainty and turnover at the FDA will slow down approval timelines and increase scrutiny.

regulatory prediction market

Implied probability (Yes)

70%

Closes

2027-12-31

Source: user-generated

More regulatory markets

• Crypto billionaire Harborne faces FCA scrutiny over £5m gift — 55% Yes
• Crypto billionaire Harborne will face FCA scrutiny — 60% Yes
• Crypto billionaire Christopher Harborne’s donation triggers FCA inquiry into funding transparency — 70% Yes
• Crypto billionaire Christopher Harborne will face parliamentary scrutiny over £5m gift — 55% Yes
• Harborne crypto holdings face regulatory scrutiny — 60% Yes
• SEC approves at least 2 new Bitcoin ETFs by Q4 2027 — 75% Yes
• SEC approves Kalshi's crypto futures products by 2026-Q3 — 55% Yes
• Iran's central bank bans crypto mining by 2027 Q1 — 85% Yes

Browse all regulatory markets →